You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Point-of-care immunoassay for early diagnosis of pertussis
SBC: DXDISCOVERY INC Topic: NIAIDDESCRIPTION provided by applicant Pertussis is a serious and potentially life threatening respiratory disease caused by the bacterium Bordetella pertussis Worldwide million people become ill with pertussis each year and of these patients die Despite high vaccine coverage in the United States there were still over pertussis cases reported in the U S in Rapid diagn ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Public Rights-of-Way Assessment Instrumentation to Determine Accessibility
SBC: BENEFICIAL DESIGNS INC Topic: N/ACities must perform detailed assessments of sidewalks and streets, including curb ramps, pedestrian signals, crosswalks, street furniture, and other components to determine compliance with the Public Rights-of-Way Accessibility Guidelines. However, current assessment methods are inadequate or unreasonable due to time and resources required. The objectives of this project are to: 1) develop elect ...
SBIR Phase I 2008 Department of Transportation -
"CULTURING AMPHIBIANS FOR BIOMEDICAL RESEARCH"
SBC: Central Valley Biological Inc Topic: N/AN/A
SBIR Phase I 1984 Department of Health and Human Services -
A NOVEL TARGETED DELIVERY SYSTEM FOR CANCER TREATMENT AND DIAGNOSIS
SBC: ENDURX PHARMACEUTICALS INC Topic: NCIDESCRIPTION (provided by applicant): Glioblastoma multiforme (GBM) or glioblastoma, is the most common and aggressive malignant primary brain tumor in humans. An effective treatment that increases patient survival would represent a significant advance inthe field, and provide a desperately needed new therapy for this deadly disease. EnduRx is focused on the development of new, targeted systems f ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
